KEY FINDINGS
The Europe clinical trial management market is predicted to record a CAGR of 12.06% during the forecast period, 2021-2028. The presence of developed healthcare infrastructure and key players are significant growth drivers of the market.
MARKET INSIGHTS
Germany, Poland, Belgium, Italy, Russia, France, the United Kingdom, and Rest of Europe, are assessed for the growth evaluation of the Europe clinical trial management market. In Germany, organizations invest a large share of their revenues in R&D across several application industries, like clinical research genomics, proteomics, and drug discovery. The country also has an active genomics sector R&D and is increasingly prioritizing research labs. Germany leads globally in terms of industry-sponsored clinical trials. This is attributed to the transparent and reliable approval processes and high level of accuracy at German trial sites. Also, the well-established network of good to excellent universities and faculties, and non-university research facilities, benefit clinical trials. Such factors supplement market growth in Germany.
In Russia, the government adopted the ‘Strategy 2020’ to enhance the pharma sector’s production capacity. Pharmaceutical companies are investing in the market. The pharmaceutical industry is projected to be driven by investments made by private players, rising healthcare expenditure, and increased government support. Also, several companies are collaborating with local universities to improve R&D capabilities. Further, the elderly population is set to double by 2050, increasing the burden on healthcare, pension, and long-term care systems. Therefore, there is a need for a robust and competent healthcare system. Moreover, the Russian market offers a competitive advantage to companies looking for alternative markets due to its developing economy. Such factors are expected to benefit the Russian market growth.
COMPETITIVE INSIGHTS
Some of the major players in the market include Oracle Corporation, Mednet Solutions Inc, Parexel International Corporation, Bioclinica Inc, IBM Corporation, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS - HEALTHCARE
3.2. MARKET SCOPE
3.3. KEY DRIVERS
3.3.1. OUTSOURCING OF CLINICAL TRIALS
3.3.2. GROWTH IN THE NUMBER OF CLINICAL TRIALS
3.3.3. AWARENESS REGARDING THE BENEFITS OF USING CTM SOFTWARE
3.3.4. INCIDENCES OF CHRONIC DISEASES
3.3.5. RESEARCH & DEVELOPMENT
3.4. KEY RESTRAINTS
3.4.1. SCARCITY OF SKILLED HEALTHCARE PROFESSIONALS
3.4.2. COST OF IMPLEMENTATION
3.4.3. SECURITY CONCERNS
4. KEY ANALYTICS
4.1. IMPACT OF COVID-19 ON CLINICAL TRIAL MANAGEMENT MARKET
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. THREAT OF SUBSTITUTION
4.3.4. THREAT OF NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. OPPORTUNITY MATRIX
4.5. VENDOR LANDSCAPE
5. MARKET BY END-USER
5.1. PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
5.2. CLINICAL RESEARCH ORGANIZATIONS
5.3. HEALTHCARE PROVIDERS
6. MARKET BY PRODUCT TYPE
6.1. ENTERPRISE-BASED CTM
6.2. SITE-BASED CTM
7. MARKET BY DEPLOYMENT MODEL
7.1. WEB-BASED DEPLOYMENT
7.2. ON-PREMISE DEPLOYMENT
7.3. CLOUD-BASED DEPLOYMENT
8. MARKET BY COMPONENT
8.1. SOFTWARE
8.2. HARDWARE
8.3. SERVICES
9. GEOGRAPHICAL ANALYSIS
9.1. EUROPE
9.1.1. MARKET SIZE & ESTIMATES
9.1.2. KEY GROWTH ENABLERS
9.1.3. KEY CHALLENGES
9.1.4. KEY PLAYERS
9.1.5. COUNTRY ANALYSIS
9.1.5.1. UNITED KINGDOM
9.1.5.2. GERMANY
9.1.5.3. FRANCE
9.1.5.4. ITALY
9.1.5.5. RUSSIA
9.1.5.6. BELGIUM
9.1.5.7. POLAND
9.1.5.8. REST OF EUROPE
10. COMPETITIVE LANDSCAPE
10.1. KEY STRATEGIC DEVELOPMENTS
10.1.1. MERGERS & ACQUISITIONS
10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
10.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
10.2. COMPANY PROFILES
10.2.1. ADVARRA (FORTE RESEARCH SYSTEMS INC)
10.2.2. ARISGLOBAL LLC
10.2.3. BIOCLINICA INC
10.2.4. BIO-OPTRONICS INC
10.2.5. IBM CORPORATION
10.2.6. MEDIDATA SOLUTIONS INC
10.2.7. MEDNET SOLUTIONS INC
10.2.8. ORACLE CORPORATION
10.2.9. PAREXEL INTERNATIONAL CORPORATION
10.2.10. VEEVA SYSTEMS INC
1. ADVARRA (FORTE RESEARCH SYSTEMS INC)
2. ARISGLOBAL LLC
3. BIOCLINICA INC
4. BIO-OPTRONICS INC
5. IBM CORPORATION
6. MEDIDATA SOLUTIONS INC
7. MEDNET SOLUTIONS INC
8. ORACLE CORPORATION
9. PAREXEL INTERNATIONAL CORPORATION
10. VEEVA SYSTEMS INC